Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-10-31
2006-10-31
Zara, Jane (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S091100, C435S455000, C435S458000, C514S001000, C514S002600, C536S023100, C424S009100
Reexamination Certificate
active
07129222
ABSTRACT:
The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a nonbiodegradable microcarrier or nanocarrier.
REFERENCES:
patent: 4458006 (1984-07-01), Dönges et al.
patent: 4458066 (1984-07-01), Caruthers et al.
patent: 4650675 (1987-03-01), Borel et al.
patent: 4849513 (1989-07-01), Smith et al.
patent: 4910300 (1990-03-01), Urdea et al.
patent: 4948882 (1990-08-01), Ruth
patent: 5015733 (1991-05-01), Smith et al.
patent: 5093232 (1992-03-01), Urdea et al.
patent: 5118800 (1992-06-01), Smith et al.
patent: 5118802 (1992-06-01), Smith et al.
patent: 5124246 (1992-06-01), Urdea et al.
patent: 5391723 (1995-02-01), Priest
patent: 5453496 (1995-09-01), Caruthers et al.
patent: 5484596 (1996-01-01), Hanna, Jr. et al.
patent: 5629158 (1997-05-01), Uhlen
patent: 5663153 (1997-09-01), Hutcherson et al.
patent: 5723335 (1998-03-01), Hutcherson et al.
patent: 5770434 (1998-06-01), Huse
patent: 5824812 (1998-10-01), Nantz et al.
patent: 5849719 (1998-12-01), Carson et al.
patent: 6086901 (2000-07-01), O'Hagan et al.
patent: 6174872 (2001-01-01), Carson et al.
patent: 6194388 (2001-02-01), Krieg et al.
patent: 6207646 (2001-03-01), Krieg et al.
patent: 6214806 (2001-04-01), Krieg et al.
patent: 6239116 (2001-05-01), Krieg et al.
patent: 6306405 (2001-10-01), O'Hagan et al.
patent: 6352975 (2002-03-01), Schreiner et al.
patent: 6355267 (2002-03-01), Collins
patent: 6458370 (2002-10-01), O'Hagan et al.
patent: 6465188 (2002-10-01), Gold et al.
patent: 6534062 (2003-03-01), Raz et al.
patent: 6544518 (2003-04-01), Friede et al.
patent: 6558670 (2003-05-01), Friede et al.
patent: 6559129 (2003-05-01), Kasid et al.
patent: 6562798 (2003-05-01), Schwartz
patent: 6589940 (2003-07-01), Raz et al.
patent: 6610661 (2003-08-01), Carson et al.
patent: 6855492 (2005-02-01), O'Hagan et al.
patent: 6884435 (2005-04-01), O'Hagan et al.
patent: 2001/0046967 (2001-11-01), Van Nest
patent: 2003/0022852 (2003-01-01), Nest et al.
patent: 2003/0059773 (2003-03-01), Van Nest et al.
patent: 2003/0129251 (2003-07-01), Van Nest et al.
patent: 2003/0133988 (2003-07-01), Fearon et al.
patent: 2003/0175731 (2003-09-01), Fearon et al.
patent: 2003/0199466 (2003-10-01), Fearon et al.
patent: 2003/0216340 (2003-11-01), Van Nest et al.
patent: 2005/0037403 (2005-02-01), Krieg et al.
patent: 0 468 520 (1992-01-01), None
patent: 0 468 520 (1992-01-01), None
patent: WO 96/02555 (1996-02-01), None
patent: WO 97/28259 (1997-08-01), None
patent: WO 98/04740 (1998-02-01), None
patent: WO 98/16247 (1998-04-01), None
patent: WO 98/18810 (1998-05-01), None
patent: WO 98/37919 (1998-09-01), None
patent: WO 98/40100 (1998-09-01), None
patent: WO 98/55495 (1998-10-01), None
patent: WO 98/52581 (1998-11-01), None
patent: WO 98/52962 (1998-11-01), None
patent: WO 98/55495 (1998-12-01), None
patent: WO 98/55495 (1998-12-01), None
patent: WO 98/55495 (1998-12-01), None
patent: WO 98/55609 (1998-12-01), None
patent: WO 99/11275 (1999-03-01), None
patent: WO 99/11275 (1999-03-01), None
patent: WO 98/33868 (1999-07-01), None
patent: WO 99/33488 (1999-07-01), None
patent: WO 99/33488 (1999-07-01), None
patent: WO 99/33868 (1999-07-01), None
patent: WO 99/51259 (1999-10-01), None
patent: WO 99/51259 (1999-10-01), None
patent: WO 99/56755 (1999-11-01), None
patent: WO 99/62923 (1999-12-01), None
patent: WO 99/62923 (1999-12-01), None
patent: WO 00/06588 (2000-02-01), None
patent: WO 00/16804 (2000-03-01), None
patent: WO 00/21556 (2000-04-01), None
patent: WO-00/54803 (2000-09-01), None
patent: WO-00/54803 (2000-09-01), None
patent: WO-00/61161 (2000-10-01), None
patent: WO-00/61161 (2000-10-01), None
patent: WO 00/67023 (2000-11-01), None
patent: WO 01/00231 (2001-01-01), None
patent: WO 01/12223 (2001-02-01), None
patent: WO 01/15726 (2001-03-01), None
patent: WO-01/22972 (2001-04-01), None
patent: WO-01/22972 (2001-04-01), None
patent: WO-01/22990 (2001-04-01), None
patent: WO-01/22990 (2001-04-01), None
patent: WO-01/35991 (2001-05-01), None
patent: WO-01/35991 (2001-05-01), None
patent: WO-01/51500 (2001-07-01), None
patent: WO-01/54720 (2001-08-01), None
patent: WO 01/68077 (2001-09-01), None
patent: WO 01/68078 (2001-09-01), None
patent: WO 01/68103 (2001-09-01), None
patent: WO 01/68116 (2001-09-01), None
patent: WO 01/68117 (2001-09-01), None
patent: WO 01/68143 (2001-09-01), None
patent: WO 01/68144 (2001-09-01), None
patent: WO 01/76642 (2001-10-01), None
patent: WO-03/015816 (2003-02-01), None
Sonehara et al. 1996 J. of Interferon and Cytokine Res. vol. 16, pp. 799-803.
Peracchi, A. et al., Rev. Med. Virol., vol. 14, pp. 47-64 (2004).
Agrawal., S. et al., Molecular Med. Today, vol. 6, pp. 72-81 (2000).
Crooke, S. Antisense Research and Application, Chapters 1 and 2, pp. 1-50, ed. by S. Crooke, Published by Springer-Verlag (1998).
Stayton, P.S. et al., J. Controlled Release, vol. 65, pp. 203-220 (2000).
Asanuma, H. et al., (1995) “Cross-protection against influenza virus infection in mice vaccined by combined nasal/subcutaneous administration”Vaccine13:3-5.
Agrawal et al. (1986). “Efficient methods for attaching non-radioactive labels to the 5′ ends of synthetic oligodeoxyribonucleotides,”Nucleic Acids Res. 14:6227-6245.
Ahmeida, E.T.S. Ben, (1993), “Immunopotentiation of local and systematic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenze A in mice,”Vaccine11(130:1302-1309.
Atherton et al. (1981). “Synthesis of a 21-residue fragment of human proinsulin by the polyamide solid phase method,”Hoppe-Seylers Z. Physiol. Chem. 362:833-839.
Ballas et al. (1996). “Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA,”J. Immunol. 157:1840-1845.
Benoit et al. (1987). “Peptides. Strategies for antibody production and radioimmunoassays,”Neuromethods6:43-72.
Bischoff et al. (1987). “Introduction of 5′-terminal functional groups into synthetic oligonucleotides for selective immobilization.”Analytical Biochemistry164:336-344.
Blanks et al. (1988). “An oligodeoxynucleotide affinity column for the isolation of sequence specific DNA binding proteins,”Nucleic Acids Res. 16:10283-10299.
Boujrad et al. (1993). “Inhibition of hormone-stimulated steroidogenesis in cultured Leydig tumor cells by a cholesterol-linked phosphorothioate oligodeoxynucleotide antisense to diazepam-binding inhibitor,”Proc. Natl. Acad. Sci. USA90:5728-5731.
Branda et al. (1993).“Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1,”Biochem. Pharmacol. 45:2037-2043.
Branda et al. (1996). “Amplification of antibody production by phosphorothioate oligodeoxynucleotides,”J. Lab. Clin. Med. 128:329-338.
Braun et al. (1988). “Immunogenic duplex nucleic acids are nuclease resistant,”J. Immunol. 141:2084-2089.
Brazolot Millan et al. (1998) “CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice,”Proc. Natl. Acad. Sci. USA95:15553-15558.
Breiteneder et al. (1989). “The gene coding for the major birch pollen allergen Betvl is highly homologous to a pea disease resistance repsonse gene,”EMBO J.8:1935-1938.
Broide et al. (1998). “Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice,”J. Immunol.161:7054-7062.
Broide et al. (1999) “DNA-based immunization for asthma,”Int. Arch. Allergy Immunol.118:453-456.
Carson et al. (1997). “Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination,”J. Exp. Med.186:1621-1622.
Chace et al. (1997). “Bacterial DNA-induced NK cell IFN-γ prod
Tuck Stephen
Van Nest Gary
Dynavax Technologies Corporation
Morrison & Foerster / LLP
Zara Jane
LandOfFree
Immunomodulatory formulations and methods for use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunomodulatory formulations and methods for use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunomodulatory formulations and methods for use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3626626